Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Lacutamab

Generic Name: Lacutamab

Drug Type: Biotech

CAS Number: 2187368-16-5

Unique Ingredient Identifier: N8O7MY0VNS

Overview

Lacutamab is under investigation in clinical trial NCT02593045 (Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)).

Background

Lacutamab is under investigation in clinical trial NCT02593045 (Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Study of Lacutamab in Peripheral T-cell Lymphoma

Phase 2

Recruiting

Posted: 2021/08/02

Sponsor:

The Lymphoma Academi...

ID:NCT04984837

IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Phase 2

Active, not recruiting

Posted: 2019/04/03

Sponsor:Innate Pharma

ID:NCT03902184

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Innate Pharma's Novel NK Cell Engager IPH6501 to Be Presented at EHA 2025 Congress

10 days ago

Innate Pharma's IPH6501, a tetraspecific NK cell engager targeting CD20 B cells for Non-Hodgkin Lymphoma, will be featured at the European Hematology Association Congress in June 2025.

Innate Pharma Doses First Patient in Phase 1 Trial of Nectin-4-Targeting ADC IPH4502 for Advanced Solid Tumors

4 months ago

Innate Pharma has initiated a Phase 1 clinical trial (NCT06781983) to evaluate the safety and tolerability of IPH4502 in patients with advanced solid tumors expressing Nectin-4.

Innate Pharma Unveils Growth Strategy and Highlights Clinical Trial Progress

5 months ago

Innate Pharma SA has announced a comprehensive strategy aimed at driving sustainable growth and innovation in pharmaceutical R&D. Key highlights include the presentation of lacutamab's quality-of-life improvements in CTCL patients, a significant investment for IPH6501 development in follicular lymphoma, and FDA clearance for a new ADC targeting solid tumors.

DATROWAY® (Datopotamab Deruxtecan) Receives EU Approval for Previously Treated Metastatic HR+/HER2- Breast Cancer

6 months ago

DATROWAY, a TROP2-directed antibody drug conjugate (ADC), has been approved in the European Union for treating adult patients with unresectable or metastatic HR+/HER2- breast cancer who have received endocrine therapy and at least one line of chemotherapy.

NK Cell Therapy Pipeline Shows Promise with Over 160 Therapies in Development

6 months ago

The NK cell therapy field is experiencing significant growth, driven by its potential to address unmet needs in cancer treatment with safer, more targeted options.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy